Sakata Y, Saito G, Sakata S, Oya Y, et al. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP). Lung Cancer 2023;186:107426.
PMID: 37992594